|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
5P50CA094056-15
|
$1,428,925
|
$85,736
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Genetically-Modified Neural Stem Cell Based Virotherapy for Invasive Gliomas
|
5R00CA160775-04
|
$239,075
|
$239,075
|
AHMED, ATIQUE
|
UNIVERSITY OF CHICAGO
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$810,831
|
$121,625
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
|
5P01CA066726-18
|
$1,182,811
|
$331,187
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer
|
5R21CA179652-02
|
$202,928
|
$50,732
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Identifying vulnerabilities and therapeutic targets in Glioma Stem Cells
|
1K22CA197053-01
|
$200,880
|
$200,880
|
BADR, CHRISTIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
4R00CA181491-02
|
$249,000
|
$124,500
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY
|
|
Platform for MR-Guided Neurotherapeutic Drug Delivery
|
2R44CA177205-02
|
$938,975
|
$469,488
|
BARKER, EDWARD
|
INSERT, INC.
|
|
Development of Targeted Therapy for ERK Pathway in Breast Cancer
|
5R00CA139006-05
|
$249,000
|
$249,000
|
BARTHOLOMEUSZ, CHANDRA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-15S1
|
$901,656
|
$108,199
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-06
|
$310,970
|
$102,620
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Histone Methyltransferases as a Target for Lung Cancer Prevention
|
5R01CA183296-02
|
$581,472
|
$290,736
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
|
SPORE: Brain Tumore SPORE Grant
|
5P50CA097257-13
|
$2,185,000
|
$109,250
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Pediatric Oncology Research Training Program
|
5T32CA009351-37
|
$259,426
|
$51,885
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
|
1R21CA193064-01
|
$1
|
$1
|
BHATNAGAR, PARIJAT
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
|
7R21CA193064-02
|
$271,339
|
$271,339
|
BHATNAGAR, PARIJAT
|
SRI INTERNATIONAL
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-04
|
$3,698,322
|
$776,648
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Research Training Program in Surgical Oncology
|
5T32CA091078-14
|
$359,864
|
$35,986
|
BLAND, KIRBY
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Optimization of a clinical stage nanoparticle drug delivery platform
|
1R43CA186410-01A1
|
$184,129
|
$92,065
|
BROWN, BOB
|
DICERNA PHARMACEUTICALS, INC.
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
5R01CA166590-03
|
$319,550
|
$159,775
|
CAO, LEI
|
OHIO STATE UNIVERSITY
|
|
Mechanisms of Chromosome Maintenance in Bacteria
|
ZIA BC 010277
|
$569,301
|
$56,930
|
Chattoraj, Dhruba
|
CCR (NCI)
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
5R01CA182528-02
|
$10,281
|
$10,281
|
CHEN, JIANJUN
|
UNIVERSITY OF CHICAGO
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-03
|
$318,441
|
$318,441
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
|
Direct coregulation of Notch1 by Zmiz1 in T-cell leukemia
|
1R01CA196604-01A1
|
$354,563
|
$177,282
|
CHIANG, MARK
|
UNIVERSITY OF MICHIGAN
|
|
Genetic Therapy for Fanconi Anemia
|
5R01CA155294-05
|
$319,550
|
$319,550
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
MOTILITY AND INVASION
|
5P01CA100324-12
|
|
$0
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
MOTILITY AND INVASION
|
6P01CA100324-13
|
$2,028,990
|
$202,899
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,108,669
|
$22,173
|
Cooper, Julia
|
CCR (NCI)
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,208,087
|
$302,022
|
Court, Donald
|
CCR (NCI)
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
5R01CA154697-05
|
$469,520
|
$469,520
|
CURIEL, DAVID
|
WASHINGTON UNIVERSITY
|
|
Natural mutagenesis of human genomes by endogenous retrotransposons
|
5R01CA166661-04
|
$318,513
|
$105,109
|
DEVINE, SCOTT
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense
|
2P01CA016038-41A1
|
$775,523
|
$100,818
|
DIMAIO, DANIEL
|
YALE UNIVERSITY
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-14
|
$1,930,400
|
$193,040
|
DINNEY, COLIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Pacific Ovarian Cancer Research Consortium
|
3P50CA083636-15S1
|
$901,655
|
$54,099
|
DRESCHER, CHARLES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$718,672
|
$718,672
|
Feldman, Steven
|
CCR (NCI)
|
|
Targeting epigenetic regulators using bacterial macromolecule delivery
|
5R01CA188382-02
|
$311,561
|
$311,561
|
FORBES, NEIL
|
UNIVERSITY OF MASSACHUSETTS AMHERST
|
|
Combination Gene Therapy and Th1/Th2 Therapy
|
ZIA BC 011219
|
$263,739
|
$131,870
|
Fowler, Daniel
|
CCR (NCI)
|
|
Developing novel strategies for altering the cytokine microenvironment of tumors
|
1R21CA184433-01A1
|
$166,931
|
$166,931
|
FRELINGER, JOHN
|
UNIVERSITY OF ROCHESTER
|
|
Gene Therapy and Radiation Therapy for Prostate Cancer
|
5R01CA160289-04
|
$303,988
|
$151,994
|
FREYTAG, SVEND
|
HENRY FORD HEALTH SYSTEM
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$707,219
|
$212,166
|
Fry, Terry
|
CCR (NCI)
|
|
Reporter Gene Technologies for Integrated Cancer Diagnostics
|
2R01CA082214-15A1
|
$375,646
|
$93,912
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
Mechanisms in Polyomavirus Assembly
|
5R01CA037667-31
|
$371,424
|
$92,856
|
GARCEA, ROBERT
|
UNIVERSITY OF COLORADO
|
|
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay
|
5R01CA151857-05
|
$317,475
|
$317,475
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
5R01CA181598-02
|
$318,513
|
$159,257
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$290,767
|
$58,153
|
Gottesman, Michael
|
CCR (NCI)
|
|
MicroRNA in Acute Myeloid Leukemia
|
5R01CA159845-05
|
$317,475
|
$317,475
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting Translation Control in Malignant Glioma
|
5R01CA124756-09
|
$253,655
|
$253,655
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
Liver Cancer Risk with rAAV Gene Therapy
|
1R01CA190144-01A1
|
$608,126
|
$608,126
|
GROMPE, MARKUS
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Uncover the mechanisms regulating the biogenesis and decay of miRNAs in cancer
|
ZIA BC 011566
|
$925,596
|
$277,679
|
Gu, Shuo
|
CCR (NCI)
|
|
Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cance
|
1R21CA191622-01
|
$203,337
|
$203,337
|
GUNDERSON, SAMUEL
|
RUTGERS, THE STATE UNIV OF N.J.
|
Total relevant funding to Gene Therapy for this search: $39,508,420
|